Navigation Links
A Recent Study by ITG's Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
Date:6/1/2011

NEW YORK, June 1, 2011 /PRNewswire/ -- A study published this week by ITG's Majestic Market Research revealed that Novartis' recently approved drug, Gilenya, continues to steal share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year.  Gilenya came onto the market in late September 2010 as the first FDA-approved oral disease-modifying MS drug.  Despite negative sentiment around Gilenya's lengthy initiation process, neurologists are embracing the new drug at an impressive rate.  Real time data from ITG's proprietary physician panel indicate that Gilenya was the disease-modifying treatment of choice for 20% of new written MS prescriptions in April.  Furthermore, surveyed neurologists indicated that their prescribing of Gilenya will increase significantly over the course of 2011 as they continue to shift inadequate responders from other MS therapies to the new drug.

The study takes an in-depth look at how Gilenya's multi-step initiation process is impacting neurologists' use of the drug.  According to neurologists, new treatment starts for Gilenya typically take between three to six weeks and involve the scheduling and organization of prescreening tests and ongoing monitoring for adverse events.  

Physicians reported that Novartis plays an important role in facilitating these steps. In fact, 63% of Gilenya prescribers indicated that they receive support from Novartis during this process, and 25% of them classified this assistance as superior to what competing companies offer for their products.  

By comparison, neurologists appear unable to get over similar concerns about Acorda Therapeutics' Ampyra, which was launched in March 2010 as the first FDA approved drug to improve walking in MS patients. Like Gilenya, Ampyra is associated with an onerous initi
'/>"/>

SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
4. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
5. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
6. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
7. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
8. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
11. Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- Researchers from the North American Menopause Society (NAMS) found ... too high, 1 putting women at risk for ... close to menopause are commonly told to take supplements ... as osteoporosis, to which they are particularly prone. ... calcium they typically get through their food sources before ...
(Date:7/23/2014)... 2014 This September leading clinicians in orthodontics ... Vegas for DOCtalk 2014 —a "Dynamic ... thinker and private practitioner Dr. David Sarver , ... discuss clinical and practice management efficiency and high quality ... opportunity to welcome fresh thinking and join a community ...
(Date:7/23/2014)... 2014 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... and research facility: Ampio Pharmaceuticals, 373 Inverness ... (720) 437-6500 Michael Macaluso , Ampio,s ... facility will be fully operational this summer, right ... Ampion TM necessary to accommodate the company,s BLA ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 22014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
... 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... a pharmaceutical company dedicated to improving healthcare through ... range of prescription and over-the-counter ("OTC") products, today ... Mr. Tony Liu and Chief Financial Officer, Ms. ...
... that a new market research report is available in ... in China http://www.reportlinker.com/p0363587/The-Top-10-CMOs-in-China.html ... and future outlook of CMO industry in China. It ... the top 10 CMOs. Other leading players are also ...
Cached Medicine Technology:American Oriental Bioengineering's CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintao's Delegation 2Reportlinker Adds The Top 10 CMOs in China 2
(Date:7/23/2014)... Adipic acid is an intermediate ... high-performance plastic, often referred to as engineering thermoplastics. ... on the monomers employed. Due to the high ... the increasing number of developing countries, the Asia-Pacific ... followed by Europe and North America. Adipic acid ...
(Date:7/23/2014)... News) -- Children and teens who lose a parent might ... a new study suggests. People who were children or ... risk of death during the study period than those who ... the report. Although the study found an association between ... death, it wasn,t designed to prove cause-and-effect. Also, the ...
(Date:7/23/2014)... at the emergency department, the drug ketamine can ... life-saving intubation, despite decades-old studies that suggested it ... systematic review of 10 recent studies of what ... are published online in Annals of Emergency ... Intracranial and Cerebral Perfusion Pressure and Health Outcomes: ...
(Date:7/23/2014)... 2014 SafeUseNow? , a ... developed by Principled Strategies , today announced ... California . Utilizing SafeUseNow’s patent-pending risk model, Partnership ... misusing and abusing controlled substance drugs, particularly prescription ... its members. , The agreement with Partnership HealthPlan ...
(Date:7/23/2014)... RFcnn.com, a distinguished electrical equipment retailer, has recently unveiled ... more, the company has decided to provide big price cuts ... an order for the company’s brand new SMA JACK can ... The high quality SMA JACK from RFcnn.com Provides a great ... electrical equipment to help make things much easier for worldwide ...
Breaking Medicine News(10 mins):Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:Ketamine can be a wonder drug for ER patients and their physicians 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 3Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 4Health News:New Collection of SMA JACK Released by China Electrical Accessory Manufacturer RFcnn 2
... GENEVA, Switzerland, December 15 Swiss-based, http://www.dnartistic.com ,s first ... million CHF and some of the proceeds will be ... of sister company, http://www.inneova.com . , ... Swiss scientist specialized in molecular,genetics of aging and co-founder ...
... Cross sheltered hundreds of people over the weekend who were affected ... Cross chapters opened shelters in Maine, Massachusetts, New Hampshire, New York ... ice storms are par for the course during the New England ... a safe and warm place to go when there are widespread ...
... VPHM ) today provided the following update regarding ... The Food and Drug Administration (FDA) has posted draft ... draft guidance is open for public comment, and if finalized ... the in vitro dissolution testing originally proposed in ...
... Dec. 15 Anthem Blue Cross and Blue Shield,(Anthem) ... life and health insurance organization, announced today that,Summerlin is ... for,its members and employer groups as it exits the ... an agreement that facilitates,the smooth transition of current Summerlin ...
... under age 65 were without health insurance for all or ... by the UCLA Center for Health Policy Research. ... California Health Interview Survey (CHIS), the policy brief,s authors found ... all or some of 2007, the most recent year for ...
... Education Virtual Lecture for Healthcare Professionals , ... Cytomegalovirus (CMV) infection is a serious condition and an ... hematopoietic stem cell transplant (HSCT) and solid organ transplant ... prevention. It is important for healthcare professionals working with ...
Cached Medicine News:Health News:DNA Jewel to Finance Anti-Aging Services & Cancer Research 2Health News:Red Cross Shelters Hundreds as Severe Weather Hits Northeast 2Health News:ViroPharma Provides Update on Vancocin(R) 2Health News:ViroPharma Provides Update on Vancocin(R) 3Health News:ViroPharma Provides Update on Vancocin(R) 4Health News:Anthem Blue Cross and Blue Shield and Summerlin Life and Health Insurance Company Enter Into Endorsement Agreement as Summerlin Announces Exit From the Commercial PPO Business in Nevada 2Health News:Anthem Blue Cross and Blue Shield and Summerlin Life and Health Insurance Company Enter Into Endorsement Agreement as Summerlin Announces Exit From the Commercial PPO Business in Nevada 3Health News:Nearly 6.4 million Californians lack health insurance, report shows 2Health News:CMV Infection in Transplant Recipients: Clinical Cases and Expert Opinion 2
... The Isoseeds I-125 are brachytherapy sources ... treatment of localized tumors, especially in the ... after the conclusion of the therapeutic effect, ... I-125 are intended for single use. They ...
Mirror prismatic gonioscope. Titanium body....
Four 62 mirrors give a 360 view of the anterior chamber angle with only a slight lens rotation. Posterior pole can be viewed through center of lens....
... mirrors allow complete observation ... little lens rotation. Small ... for eyes with small ... ring available in small ...
Medicine Products: